Marinus Pharmaceuticals, Inc. (MRNS) Reaches $6.29 After 9.00% Down Move; Digimarc (DMRC) Shorts Down By 13.22%

February 16, 2018 - By Migdalia James

Digimarc Corporation (NASDAQ:DMRC) had a decrease of 13.22% in short interest. DMRC’s SI was 1.46 million shares in February as released by FINRA. Its down 13.22% from 1.68M shares previously. With 45,400 avg volume, 32 days are for Digimarc Corporation (NASDAQ:DMRC)’s short sellers to cover DMRC’s short positions. The SI to Digimarc Corporation’s float is 16.36%. The stock increased 1.49% or $0.45 during the last trading session, reaching $30.75. About 23,790 shares traded. Digimarc Corporation (NASDAQ:DMRC) has risen 20.66% since February 16, 2017 and is uptrending. It has outperformed by 3.96% the S&P500.

The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is a huge mover today! The stock decreased 1.87% or $0.12 during the last trading session, reaching $6.29. About 402,786 shares traded. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has declined 74.89% since February 16, 2017 and is downtrending. It has underperformed by 91.59% the S&P500.The move comes after 6 months negative chart setup for the $254.31M company. It was reported on Feb, 16 by Barchart.com. We have $5.72 PT which if reached, will make NASDAQ:MRNS worth $22.89M less.




Among 4 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Marinus Pharmaceuticals had 9 analyst reports since August 5, 2015 according to SRatingsIntel. Jefferies maintained Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) rating on Tuesday, June 14. Jefferies has “Buy” rating and $2.50 target. Oppenheimer maintained Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) rating on Friday, October 30. Oppenheimer has “Outperform” rating and $17 target. The stock has “Sector Perform” rating by RBC Capital Markets on Tuesday, June 14. The firm has “Buy” rating given on Wednesday, August 10 by Jefferies. The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) earned “Outperform” rating by RBC Capital Markets on Thursday, December 17. The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has “Buy” rating given on Tuesday, March 8 by Stifel Nicolaus. Oppenheimer maintained it with “Outperform” rating and $21 target in Wednesday, August 5 report. Oppenheimer downgraded the stock to “Perform” rating in Tuesday, June 14 report. The rating was initiated by Jefferies with “Buy” on Tuesday, November 17.

Since December 15, 2017, it had 0 insider purchases, and 2 insider sales for $10.05 million activity. The insider Smith Edward F sold 3,000 shares worth $23,730. $10.02M worth of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was sold by Bain Capital Life Sciences Investors – LLC.

Investors sentiment increased to 2.8 in Q3 2017. Its up 2.26, from 0.54 in 2017Q2. It increased, as 8 investors sold Marinus Pharmaceuticals, Inc. shares while 2 reduced holdings. 20 funds opened positions while 8 raised stakes. 18.97 million shares or 171.42% more from 6.99 million shares in 2017Q2 were reported. Perceptive Advisors Ltd reported 0.33% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). 1.36M are owned by Deerfield Mgmt. Ellington Mgmt Gru Lc has invested 0.05% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Blackrock accumulated 181,359 shares. Susquehanna Interest Group Ltd Liability Partnership holds 0% or 85,618 shares. 12,007 were reported by Arrowmark Colorado Limited Liability Corp. Orbimed Advsrs holds 0.03% or 567,600 shares in its portfolio. J Goldman & Company Lp owns 54,000 shares. Shanda Asset Management Hldgs Ltd holds 0.01% or 10,000 shares in its portfolio. State Street reported 0% stake. 835,263 are held by Vanguard Grp Inc. Millennium Management Ltd Com holds 0.01% or 867,927 shares in its portfolio. Farallon Ltd Liability Com invested 0.06% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Jennison Assoc owns 1.61M shares. Bogle Inv Limited Partnership De reported 382,619 shares.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company has market cap of $254.31 million. The firm is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. It currently has negative earnings. The firm is also developing ganaxolone IV formulation to treat status epilepticus.

Digimarc Corporation provides media identification and management solutions to commercial entities and government clients in the United States and internationally. The company has market cap of $342.86 million. It primarily offers Digimarc Discover, and Digimarc Barcode and Intuitive Computing Platform that are designed to optimize the identification of various consumer brand impressions facilitating mobile-centric shopping. It currently has negative earnings. The companyÂ’s solutions identifies, tracks, manages, and protects content; and enables new consumer applications to access networks and information from personal computers and mobile devices.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: